Pharmaceuticals

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

* Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) * Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net a...

2024-07-23 01:23 3252

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...

2024-07-22 19:48 3804

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...

2024-07-22 19:00 3312

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...

2024-07-22 09:00 2763

Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors

HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 21, 2024 /PRNewswire/ -- Full-Life Technologies, a fully integrated global radiotherapeutics company, today announcedthe appointment of Ted Myles to Full-Life's Board of Directors. Mr. Myles will serve as chairman of the audit c...

2024-07-22 08:00 1946

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-07-22 08:00 4319

Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration

SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) fo...

2024-07-19 22:01 5713

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

* Financing led by LongRiver Investments with participation by new and existing global investment funds * Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond SHANGHAI, July 19, 2024 /...

2024-07-19 12:30 4441

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-07-19 07:15 3801

ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development

NEWARK, Del., July 18, 2024 /PRNewswire/ -- At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting inHamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) developme...

2024-07-19 00:00 3350

Assessment of supply chain risk key to improving medicine access

A four-year research project by INSEAD and five other institutions sheds light on how understandingmedical criticality, supply chain risk and their interactions could help us better address drug shortages. FONTAINEBLEAU, France, SINGAPORE and SAN FRANCISCO, July 18, 2024 /PRNewswire/ -- Drug s...

2024-07-18 23:00 3131

DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment

* Confirmation of effects compared to global late-stage clinical trials * Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining att...

2024-07-18 21:00 3384

Duoning showcases its comprehensive bioprocess solutions at Interphex Korea 2024

SHANGHAI, July 18, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess solution provider, announced it has attended at Interphex Korea 2024 to showcase its total bioprocess solutions for the preparation of diverse biological products. Interphex 2024 provide...

2024-07-18 20:00 2669

Pfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong

* The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities inHong Kong and Macau earlier, and is available inHong Kong this month (July 2024) * Helps fight against RSV in older adults aged 60 and above and infants (throu...

2024-07-18 14:41 2423

MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference

* MicuRx showcased the latest research progress on their pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis Conference * Three significant study results further support the potential of MRX-5 and MRX-8 in treating Nontuberculous Mycobacteria (NTM) lung disease and Pseudomonas...

2024-07-18 13:19 2060

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced thatChina's National Medical Products ...

2024-07-18 08:00 2987

Increasing Possibility of Success by Expanded Antibody Repertoires with Lambda Light Chain - Immunocan Launches New Mouse Strain of Fully Human Antibody Platform: ImmuMab® HKL Mouse

BOSTON, July 17, 2024 /PRNewswire/ -- Immunocan announced the successful construction of new strain of fully human antibody platform: ImmuMab® HKL mouse. This new mouse was created by in-situ replacing the variable region of Immunoglobulin genes of mouse by its counterparts from human. With Lambd...

2024-07-17 21:50 1957

First procedure in Netherlands with NaoTrac surgical navigation robot is performed at Erasmus MC Rotterdam

HSINCHU, July 17, 2024 /PRNewswire/ -- Brain Navi announces the completion of its first case inNetherlands, which was successfully and safely performed at Erasmus MC inRotterdam, Netherlands. Brain biopsy helps doctors decide the best treatment for the patient after taking a tissue sample from t...

2024-07-17 15:49 2887

111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024

SHANGHAIJuly 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will partic...

2024-07-17 13:31 2042

GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities

* Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis * Including blockbuster drugs such as 'Keytruda' and 'Yervoy', GCCL offers tailored clinical trial analysis services for biosimilar development YONGIN, South Korea...

2024-07-17 10:38 2328
1 ... 106107108109110111112 ... 339